Phcog.Net logo
Submit

BROWSE ALL JOURNALS

    SEE ALL 6 JOURNALS
    Pharmacognosy MagazineNOW IN
    Article

    Potency of Massoia Bark in Combating Immunosuppressed‑related Infection

    Triana Hertiani2,3★, Sylvia Utami Tunjung Pratiwi2,3, Agustinus Yuswanto4, Prisci Permanasari2★ Corresponding author

    1. 1Centre for Natural Antiinfective Research, Faculty of Pharmacy, Gadjah Mada University, Departments of, Indonesia.
    2. 2Pharmaceutical Biology and, Indonesia.
    3. 3Pharmaceutical Chemistry, Faculty of Pharmacy, Gadjah Mada University, Yogyakarta, Indonesia.

    CORRESPONDENCE

    Triana Hertiani

    Pharmaceutical Biology and, Indonesia.

    hertiani@ugm.ac.id

    Received: 06-06-2015; Revised: 14-07-2015.

    Volume 12, Issue 46s · pp. S363–S370 · PUBLISHED 7 July 2016 · DOI: 10.4103/0973-1296.185771

    View on Pharmacogn. Mag. original site ↗

    ABSTRACT

    Background: As part of our search for new potential natural resources to eradicate infection, we have revealed the prominent potency of massoia bark (Massoia aromatica Becc, Lauraceae) in combating immunosuppressed‑related infection. Materials and Methods: The extract was prepared by macerating the pulverized dried bark in ethanol 95%, followed by solvent evaporation. The oil was extracted from the dried bark by steam‑hydrodistillation of which preparative thin‑layer chromatography was performed on the oil to isolate the active constituent, C‑10 massoia lactone (ML). Anti‑biofilm assay against Candida albicans was conducted on polystyrene 96 wells microtiter plates, followed by a confocal laser scanning microscope observation to get three‑dimensional profiles of the affected biofilms. Effects on the hyphae development inoculated on RPMI‑1640 agar plates were observed for 7 days. Influences of samples on mice macrophage phagocytosis were examined by an in vitro technique. Samples concentration tested were in the range of 2.0–0.0625 mg/mL and done in triplicate. Results: Massoia bark extracts (oil and solid phase) and ML exhibited promising activities as anti‑biofilm against C. albicans at IC50 0.074% v/v, 271 µg/mL and 0.026 µg/mL, respectively. The ML did not inhibit the hyphae development at the concentration tested; however, the extracts showed inhibition at 62.5 μg/mL. Macrophage phagocytosis stimulation was correlated to the ML content. Conclusion: Massoia bark is potential to be developed as anti‑infective in immunosuppressed condition of which the C10 ML (C10H16O2) plays a major role in exerting activity.

    KEYWORDS

    Open in new tab

    REFERENCES

    As published

    Showing references and in-text citations exactly as published.

      Cite this article

      SELECT FORMAT

      Hertiani, T., Pratiwi, S. U. T., Yuswanto, A., & Permanasari, P. (2016). Potency of Massoia Bark in Combating Immunosuppressed‑related Infection. Pharmacognosy Magazine, 12(46s), S363–S370. https://doi.org/10.4103/0973-1296.185771